The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Participant has regular menstrual cycles ≥24 days and ≤34 days
A minimum 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition
A history of menstrual migraine attacks of at least 3 months
Participant reported history of experiencing at least 1 migraine attack during the perimenstrual period in at least 2 out of 3 menstrual cycles immediately prior to screening.
Greater than 6 migraine days per month that are outside of the perimenstrual period in the 3 months prior to Screening
A diagnosis of chronic migraine or a history of more than 14 headache days per month on average, in the 3 months prior to Screening
History of retinal migraine, basilar migraine or hemiplegic migraine
Current diagnosis of schizophrenia, bipolar, or borderline personality disorder